

REQUIRED ITEMS

1. Pathology Report 2. Clinical Information 3. Face Sheet (Front and Back Copy of the Patient's Insurance Card and Demographic Information) 4. Provider's Signature

PATIENT INFORMATION

Last Name _____
 First Name _____ M.I. _____
 DOB ____/____/____ Gender: Male Female Other _____
 Address _____
 City _____ State _____ Zip _____
 Phone _____ Patient ID _____

PROVIDER INFORMATION

Authorized Signature _____ Date _____
 Please Fax Duplicate Report to Provider _____ Fax _____

BILLING INFORMATION

Bill to: Insurance Medicare Referring Facility (Hospital/Client) Split Billing - Client (TC) and Insurance (PC) Patient
 Patient Status: Inpatient (Hospital) Outpatient (Hospital) Non-Hospital ASC Prior Authorization # _____

CLINICAL INFORMATION

Indication(s) for Testing: _____
 ICD-10 Codes: _____ Disease: New Diagnosis Refractory Recurrent/Relapsed Follow-Up

SPECIMEN INFORMATION

Date Collected ____/____/____ Specimen Site _____ BREAST BIOPSY, Fixation Time _____ : _____
 Specimen ID _____ FFPE BLOCK, # of Blocks _____
 Date Retrieved ____/____/____ Date Discharged ____/____/____ FRESH TISSUE, Media Type _____
 UNSTAINED SLIDES, # of Slides _____ Slide Thickness _____ H&E BLOOD FOR MSI ANALYSIS (EDTA ONLY: PURPLE TOP)
 SPECIMEN PICK UP, I would like CorePath to request block from facility. Facility Name _____ Phone _____ Fax _____
 Address _____ City _____ State _____ Zip _____

TEST REQUESTED (FOR MORE TESTING INFORMATION, VISIT COREPATH.US)

TumorCORE 20/20 EVALUATION
 Pathology Consultation w/Morphologic Interpretation and/or Ancillary Studies (IHC, FISH and/or PCR, and NGS); if clinically indicated.

BREAST CANCER
 ER/PR/HER2 (IHC) PD-L1 (SP142) IHC (for TECENTRIQ®)
 Reflex to HER2 FISH if HER IHC result is 2+ HER2 Amplification (FISH) (FDA)
 Ki67 (IHC) PIK3CA Mutation (for PIQRAY® Therapy) (PCR)
 TP53 (IHC) oncotypeDX® (Breast Recurrence Score)
 oncotypeDX® (Breast DCIS Score)
 MammaPrint Assay

BRAIN TUMORS
 EGFR Amplification (FISH) IDH1/IDH2 Mutation (PCR)
 MYCN Amplification (FISH) MGMT Promoter Methylation (PCR)
 BRAF V600E Mutation Analysis (PCR) TERT Promoter Methylation (PCR)
 PTEN Mutation Analysis NTRK & RET Fusion Profile (NGS)

BLADDER CANCER
 PD-L1 IHC 22C3 (FDA) (for KEYTRUDA®) FGFR 2 & 3 Mutation (for Balversa™) (FDA) (PCR)
 PD-L1 (SP142) IHC (for TECENTRIQ®) Urovysion (FISH) (FDA)
 PD-L1 IHC 28-8 (for OPDIVO®) PIK3CA Mutation
 PD-L1 (SP263) IHC (for IMFINZI®) PTEN Mutation

COLORECTAL CANCER
 Microsatellite Instability (MSI) Analysis* KRAS/NRAS/BRAF Mutation
 MLH1, MSH2, MSH6, PMS2 (IHC) KRAS Mutation (exons 2, 3 & 4)
 BRAF V600E Mutation NRAS Mutation (exons 2 & 3)
 If negative, reflex to MLH1 Promoter Methylation PIK3CA Mutation (PCR)

**Normal tissue is required.*
GASTRIC CANCER
 PD-L1 IHC 22C3 (FDA) (for KEYTRUDA®) HER2 Amplification (FISH)

GASTROINTESTINAL STROMAL TUMORS (GIST)
 PDGFRA Mutation KIT Mutation

MELANOMA
 BRAF V600E/K Mutation NRAS Mutation
 KIT Mutation PD-L1 IHC 28-8 (for OPDIVO®)

GYNECOLOGICAL TUMORS (UTERUS/OVARY/FALLOPIAN TUBE/PERITONEUM)
 PD-L1 IHC 22C3 for Cervical Cancer (FDA) (for KEYTRUDA®) MSI Analysis (PCR)*
 BRAF V600E Mutation (PCR) MLH1 Promoter Methylation (PCR)
 KRAS Mutation (exons 2, 3 & 4) (PCR) PIK3CA Mutation
 PTEN Mutation
**Normal tissue is required.*

LUNG CANCER
 PD-L1 IHC 22C3 (FDA) (for KEYTRUDA®) ROS1 Rearrangement (FISH)
 PD-L1 (SP142) IHC (for TECENTRIQ®) MET Amplification (FISH)
 PD-L1 IHC 28-8 (for OPDIVO®) MET exon 14 Deletion (PCR)
 PD-L1 (SP263) IHC (for IMFINZI®) FGFR1 Amplification (FISH)
 EGFR Mutation (PCR) KRAS Mutation (exons 2, 3 & 4) (PCR)
 If negative, reflex to ALK/ROS1 Rearrangement BRAF V600E Mutation (PCR)
 ALK Rearrangement (FDA) (FISH) NTRK NGS Fusion Profile
 Oncomine Dx Test (FDA)

PROSTATE CANCER
 PTEN Deletion (FISH) ERG Rearrangement (FISH) oncotypeDX® (Genomic Prostate Score)
 PTEN Sequence Analysis Androgen Receptor (AR) Mutation

THYROID CANCER
 KRAS/NRAS/HRAS Mutation (PCR) HRAS Mutation (exons 2 & 3) (PCR)
 KRAS Mutation (exons 2, 3 & 4) (PCR) BRAF V600E Mutation (PCR)
 NRAS Mutation (exons 2 & 3) (PCR) PIK3CA Mutation
 NTRK & RET Fusion Profile (NGS)

SARCOMAS
 FOXO1 (13q16) Rearrangement (FISH) SS18 (SYT) (18q11) Rearrangement (FISH)
 EWSR1 (22q12) Rearrangement (FISH) MDM2 Amplification (FISH)
 DDIT3 (12q13) Rearrangement (FISH)

NEXT-GENERATION SEQUENCING (NGS)
 Solid Tumor Profile (DNA)** Solid Tumor Profile Plus Fusion (DNA and RNA)
 Solid Tumor Fusion Profile (RNA)** Liquid Biopsy Profile (Blood; EDTA Only)
*** 434 genes *** 55 genes*

OTHER _____

LABORATORY USE ONLY